Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Loretta M, Itri"'
Autor:
Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/abb00ee86ac244e6959147aeb2f4a725
Autor:
Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Sacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate with an SN-38 payload. In the ASCENT study, patients with metastatic triple-negative breast cancer (mTNBC) relapsed/refractory to ≥2 prior chemotherapy regimens (≥1 in
Externí odkaz:
https://doaj.org/article/d9b62774a9d24a4da2cdc08d0bf5a33c
Autor:
Martin Olivo, Priyanka Sharma, Sara A. Hurvitz, Javier Cortes, Quan Hong, Eva Maria Ciruelos Gil, Sara M. Tolaney, Erika Hamiltion, Kevin Kalinsky, Joyce O'Shaughnessy, Philippe Aftimos, Loretta M. Itri, Linda T. Vahdat, Delphine Loirat, Lisa A. Carey, Véronique Diéras, Michaela Tsai, Tiffany A. Traina, Amelia Zelnak, David M. Goldenberg, Florence Dalenc, Sabela Recalde, Hope S. Rugo, Kevin Punie, Sagar Sardesai, Mafalda Oliveira, Aditya Bardia
Publikováno v:
Cancer Research. 81:GS3-06
Background: Trophoblast cell-surface antigen-2 (Trop-2) is highly expressed in many epithelial tumors, including triple-negative breast cancer (TNBC). Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2 antibody couple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f775a95f47fb7f11c04bcf4bbfa9b2f0
https://doi.org/10.1158/1538-7445.sabcs20-gs3-06
https://doi.org/10.1158/1538-7445.sabcs20-gs3-06
Autor:
Quan Hong, Martine Piccart, Delphine Loirat, Martin Olivo, Luca Gianni, Véronique Diéras, Sara A. Hurvitz, Aditya Bardia, Lisa A. Carey, Sibylle Loibl, Sara M. Tolaney, Joyce O'Shaughnessy, Loretta M. Itri, Hope S. Rugo, Javier Cortes, David M. Goldenberg, Kevin Punie, Kevin Kalinsky
Publikováno v:
Cancer Research. 81:PS11-09
Background: Trophoblast cell-surface antigen-2 (Trop-2) is highly expressed in many epithelial tumors, including triple-negative breast cancer (TNBC). Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2 antibody couple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5031a38bb2fd934697a73d0475f7ade7
https://doi.org/10.1158/1538-7445.sabcs20-ps11-09
https://doi.org/10.1158/1538-7445.sabcs20-ps11-09
Autor:
Brooke R. Daniel, Leonard Klein, Kevin Kalinsky, Tiffany A. Traina, Quan Hong, Filipa Lynce, Martin Olivo, Loretta M. Itri, Foluso O. Ademuyiwa, Véronique Diéras, Robert Weaver, Hope S. Rugo, Aditya Bardia, Delphine Loirat, Kevin Punie, David M. Goldenberg, Adam Brufsky, Sara A. Hurvitz, Lisa A. Carey, Sara M. Tolaney
Publikováno v:
Cancer Research. 81:PD13-07
Background: Patients (pts) with metastatic triple-negative breast cancer (mTNBC) who have brain metastases represent a poor prognosis cohort with a high unmet clinical need. Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::151369cc5795c962d4d7a9743375a104
https://doi.org/10.1158/1538-7445.sabcs20-pd13-07
https://doi.org/10.1158/1538-7445.sabcs20-pd13-07
Autor:
Lee D. Cranmer, Andrew J. Wagner, Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian A. Van Tine, Rashmi Chugh, Erlinda M. Gordon, David J. Kwiatkowski, Jason L. Hornick, Heng Du, Li Ding, Anita N. Schmid, Willis H. Navarro, Loretta M. Itri, Mark A. Dickson
Publikováno v:
Cancer Research. 83:LB288-LB288
nab-Sirolimus is an mTOR inhibitor (mTORi) approved in the US for the treatment of adult patients with locally advanced, unresectable, or metastatic malignant perivascular epithelioid cell tumor (PEComa) based on clinical efficacy and safety data fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fe846a7105c0beb48d86b664604e7a8
https://doi.org/10.1158/1538-7445.am2023-lb288
https://doi.org/10.1158/1538-7445.am2023-lb288
Autor:
Jordi Rodon Ahnert, Brian Schulte, Michael J. Demeure, Dustin Deming, Noah Federman, Meredith A. McKean, Elizabeth Lee, Alexander Spira, David J. Kwiatkowski, Maen Hussein, Erlinda Gordon, David Crockett, Kristen Ganjoo, Lee D. Cranmer, Anita N. Schmid, Willis H. Navarro, Loretta M. Itri, Gopa Iyer
Publikováno v:
Cancer Research. 83:CT057-CT057
nab-Sirolimus is a novel albumin-bound mTOR inhibitor (mTORi) approved in the US for adult patients with malignant PEComa. In an exploratory analysis of the pivotal AMPECT trial of nab-sirolimus in advanced malignant PEComa (NCT02494570), 8/9 (89%) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::642b0fafe03034aa67ce8dcaf19ab603
https://doi.org/10.1158/1538-7445.am2023-ct057
https://doi.org/10.1158/1538-7445.am2023-ct057
Autor:
Scott T. Tagawa, Yohann Loriot, Daniel P. Petrylak, Loretta M. Itri, Arjun Vasant Balar, Trishna Goswami, Aude Flechon, Quan Hong, Manojkumar Bupathi, Arash Rezazadeh Kalebasty, Rohit Jain, Petros Grivas, Christos Kyriakopoulos, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Cora N. Sternberg, Neeraj Agarwal, Damien Pouessel
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(22)
PURPOSE Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b8846a328556d2ad30e5680094f203
https://pubmed.ncbi.nlm.nih.gov/34491818
https://pubmed.ncbi.nlm.nih.gov/34491818
Autor:
Aditya, Bardia, Sara A, Hurvitz, Sara M, Tolaney, Delphine, Loirat, Kevin, Punie, Mafalda, Oliveira, Adam, Brufsky, Sagar D, Sardesai, Kevin, Kalinsky, Amelia B, Zelnak, Robert, Weaver, Tiffany, Traina, Florence, Dalenc, Philippe, Aftimos, Filipa, Lynce, Sami, Diab, Javier, Cortés, Joyce, O'Shaughnessy, Véronique, Diéras, Cristiano, Ferrario, Peter, Schmid, Lisa A, Carey, Luca, Gianni, Martine J, Piccart, Sibylle, Loibl, David M, Goldenberg, Quan, Hong, Martin S, Olivo, Loretta M, Itri, Hope S, Rugo, Amelia, Zelnak
Publikováno v:
The New England journal of medicine. 384(16)
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the major
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70029c4dd863b4c6dc4a6d2e33ebdee0
https://pubmed.ncbi.nlm.nih.gov/36467370
https://pubmed.ncbi.nlm.nih.gov/36467370
Autor:
Quan Hong, Martin Olivo, Sara M. Tolaney, Sara A. Hurvitz, Javier Cortes, Kevin Punie, Aditya Bardia, Michaela L. Tsai, Kevin Kalinsky, Michael A. Danso, Filipa Lynce, Hope S. Rugo, Florence Dalenc, Mafalda Oliveira, Stéphanie Henry, Loretta M. Itri, Alejandra T. Perez, Joyce O'Shaughnessy, Priyanka Sharma
Publikováno v:
Journal of Clinical Oncology. 39:1077-1077
1077 Background: In pts with pretreated mTNBC, standard-of-care chemotherapy is associated with low objective response rates (ORRs) and short median progression-free survival (PFS). SG is an antibody-drug conjugate composed of an anti–Trop-2 antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e07684508c8a40e8b88658b807df63c
https://doi.org/10.1200/jco.2021.39.15_suppl.1077
https://doi.org/10.1200/jco.2021.39.15_suppl.1077